Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
News & Articles
The Phase 1 trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was imple
Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK - 20th F
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for O
The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix Oxford, UK - 16th Janu
Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Pre
Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK - 13th December 2024
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English